TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26635039

Group type: EXPERIMENTAL
Intervention: Peripheral blood complete molecular remission monitoring every 3 months
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Molecular relapse confirmed on subsequent peripheral blood sample
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Bone marrow complete molecular remission
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Monitoring of minimal residual disease
Number of subjects: 94
Study: 26635076

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Reduced eGFR (continuous variable)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Indices of cardiac mechanics (after adjustment)
Number of subjects: 299
Study: 26635230

Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers (CYP3A5*1 allele carriers)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CYP3A5 nonexpressers (homozygous CYP3A5*3)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Both groups (CYP3A5 expressers and nonexpressers)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CYP3A5 nonexpressers
Number of subjects: 164
Study: 26635965

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention followed by standard fertility treatments after 6 months if no conception has been achieved
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard fertility treatments only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100
Study: 26636013

Group type: EXPERIMENTAL
Intervention: Weekend prescribing (Friday to Sunday)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Weekday prescribing (Monday to Thursday)
Number of subjects: 30
Study: 26636489

Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 26637464

Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapies (ACTs) during early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregnant women without malaria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregnant women treated for malaria but exposed to other antimalarials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregnant women with malaria treated with artemisinins in the 2nd or 3rd trimesters
Number of subjects: 0
Study: 26637645

Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST) of the less-affected ankle dorsiflexor muscles, 16 to 18 high-intensity training sessions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST)
Number of subjects: 8
Study: 26638054

Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET) using treadmill (n=96) and cycle-ergometer (n=106)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET) using treadmill (n=96)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET)
Number of subjects: 202
Study: 26639081

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 54
Study: 26639348

Group type: EXPERIMENTAL
Intervention: Venetoclax (150 to 1200 mg per day in dose-escalation phase; up to 400 mg per day in expansion cohort)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg per day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 116
Study: 26639390

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 15
Study: 26639404

Group type: EXPERIMENTAL
Intervention: Inducible caspase-9 gene (iC9) safety switch expressed by donor-derived T lymphocytes, activated by chemical inducer of dimerization (CID).
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: iC9-T cells detectable post-CID.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vector insertion sites (VIS) in iC9-T cells pre- and post-CID administration.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Analysis of VIS locations.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Suboptimal iC9 transgene expression.
Number of subjects: 4
Study: 26640039

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg daily) combined with Rituximab (375 mg/m2 IV once per week for 4 weeks, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with Rituximab
Number of subjects: 50
Study: 26640780

Group type: EXPERIMENTAL
Intervention: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized trivalent bispecific antibody (TF2) and IMP288 bivalent HSG peptide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: S1 imaging session
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TF2 pharmacokinetics (PK)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: (111)In- and (177)Lu-IMP288 pharmacokinetics (PK)
Number of subjects: 9
Study: 26640956

Group type: EXPERIMENTAL
Intervention: Peg-IFN/RBV plus NTZ
Number of subjects: 21

Group type: COMPARATOR
Intervention: Peg-IFN/RBV (historical cohort)
Number of subjects: 21
Study: 26641137

Group type: EXPERIMENTAL
Intervention: Acalabrutinib (100 to 400 mg once daily in phase 1, 100 mg twice daily in phase 2)
Number of subjects: 61
Study: 26643677

Group type: EXPERIMENTAL
Intervention: Autologous cord blood transfusion within 5 days postpartum (n = 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Allogeneic red blood cell transfusion when necessary (n = 9; control group)
Number of subjects: 14
Study: 26643737

Group type: EXPERIMENTAL
Intervention: Successful drug-eluting stent implantation
Number of subjects: 8454

Group type: EXPERIMENTAL
Intervention: Non-periprocedural MI
Number of subjects: 8454
Study: 26643807

Group type: EXPERIMENTAL
Intervention: Enzastaurin (LY317615) and bevacizumab
Number of subjects: 81
Study: 26644412

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant (HCT) after GO
Number of subjects: 183
Study: 26644956

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 3384

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 3384

Group type: COMPARATOR
Intervention: Desvenlafaxine
Number of subjects: 3384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3384
Study: 26644957

Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended release (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26645295

Group type: EXPERIMENTAL
Intervention: Ataxia-telangiectasia patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 26645405

Group type: EXPERIMENTAL
Intervention: Carboplatin administered intravenously for 60 min after blood-brain barrier disruption using an implantable ultrasound device.
Number of subjects: 1
Study: 26645414

Group type: EXPERIMENTAL
Intervention: MMP-1, -2, -3, -8, -9, -10 and IL-6, IL-8 levels in COPD patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MMP-3, -7, -8, -9, -10 and -12 concentrations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MMP-3, -7, -10
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pulmonary MMP concentrations
Number of subjects: 32
Study: 26645477

Group type: EXPERIMENTAL
Intervention: Pre-engagement with trial sites (contacting directors and obtaining letters of intent)
Number of subjects: 33
Study: 26645559

Group type: EXPERIMENTAL
Intervention: SeptiCyte Lab (four-gene classifier combining CEACAM4, LAMP1, PLA2G7, and PLAC8 RNA biomarkers)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 450
Study: 26645682

Group type: EXPERIMENTAL
Intervention: GA/GG genotype of AKT2: rs33933140
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: GT/GG genotype of PI3CA: rs9838117
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: CT/TT genotype of AKT2: rs11880261
Number of subjects: 261
Study: 26645894

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in early life
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 450
Study: 26646040

Group type: EXPERIMENTAL
Intervention: Attenuated Psychosis Syndrome (APS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-APS youth
Number of subjects: 89
Study: 26646680

Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 57

Group type: COMPARATOR
Intervention: nevirapine-based ART
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ART-naive
Number of subjects: 57
Study: 26646811

Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Lower education level
Number of subjects: 1092
Study: 26646818

Group type: EXPERIMENTAL
Intervention: Baseline optimism
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Baseline gratitude
Number of subjects: 164
Study: 26646829

Group type: EXPERIMENTAL
Intervention: Ultra-low dose IL-2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Initial learning phase with six different doses and frequencies of IL-2
Number of subjects: 36
Study: 26647079

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 0
Study: 26647082

Group type: EXPERIMENTAL
Intervention: Internal Mammary Artery (IMA) failure
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Predictors of IMA graft failure
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Subsequent clinical outcomes related to IMA failure
Number of subjects: 1539
Study: 26647281

Group type: EXPERIMENTAL
Intervention: DC-based vaccine loaded with autologous HIV-1-infected apoptotic cells
Number of subjects: 10
Study: 26647431

Group type: EXPERIMENTAL
Intervention: Bedaquiline for 24 weeks with a background regimen of anti-TB drugs
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Bedaquiline treatment
Number of subjects: 233
Study: 26647450

Group type: EXPERIMENTAL
Intervention: Plethysmographic pulse amplitude ratio during Valsalva maneuver
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Plethysmographic pulse amplitude ratio
Number of subjects: 102
Study: 26647454

Group type: EXPERIMENTAL
Intervention: Group 3 (action and maintenance)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Group 1 (pre-contemplation and contemplation)
Number of subjects: 55
Study: 26647901

Group type: EXPERIMENTAL
Intervention: ICBT program
Number of subjects: 91
Study: 26648747

Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy (placebo-controlled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26649075

Group type: EXPERIMENTAL
Intervention: MBP-NC (200 mg red yeast rice extract, 500 mg berberine, 10 mg policosanols)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26649337

Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound (CEUS) with 2.4 ml SonoVue
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Contrast CT/MRI and biopsy (reference methods)
Number of subjects: 1153
Study: 26649807

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with docetaxel (weekly cetuximab: first infusion 400 mg/m², then 250 mg/m²; docetaxel: 100 mg/m² every 3 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with docetaxel
Number of subjects: 35
Study: 26650227

Group type: EXPERIMENTAL
Intervention: BI 847325 (Schedule A, 2 weeks on, 1 week off, starting at 6 mg, MTD 120 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BI 847325 (Schedule B, three periods of 5 days on, 2 days off, MTD 150 mg/day)
Number of subjects: 69
Study: 26651157

Group type: EXPERIMENTAL
Intervention: Tympanometry (type A and C1 tympanograms with tympanometric peak pressure >-200 daPa)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Spectral gradient acoustic reflectometry (SG-AR level 1 result >95°)
Number of subjects: 281
Study: 26652141

Group type: EXPERIMENTAL
Intervention: Chinese Cardiac Surgery Registry (CCSR)
Number of subjects: 46303
Study: 26652184

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination combined with low-dose cyclophosphamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide
Number of subjects: 10
Study: 26653566

Group type: EXPERIMENTAL
Intervention: ESPEN formula using body weight (BW)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Predictive equations including minute ventilation and body temperature
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Measured body weight (BW)
Number of subjects: 85
Study: 26653680

Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial iron overload (n=19, 63.3%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial iron overload
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients without iron overload
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of ECV with lowest historical T2*
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of ECV with left ventricular ejection fraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of ECV with global longitudinal strain
Number of subjects: 30
Study: 26653754

Group type: EXPERIMENTAL
Intervention: Opioid substitution therapy
Number of subjects: 2500
Study: 26654128

Group type: EXPERIMENTAL
Intervention: Hippocampal sparing during whole brain radiotherapy (HS-WBRT)
Number of subjects: 40
Study: 26654474

Group type: EXPERIMENTAL
Intervention: Evidence-based psychotherapy (EBP) offered for PTSD
Number of subjects: 324
Study: 26654630

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Plasma exchange/plasma infusion
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Kidney transplant
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Family history of aHUS
Number of subjects: 516
Study: 26654720

Group type: EXPERIMENTAL
Intervention: Pregnant women with a lifetime diagnosis of schizophrenia, bipolar disorder, major depressive disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-psychiatric control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver-infant interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal caregiver representation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0
Study: 26655841

Group type: EXPERIMENTAL
Intervention: 1 or 2 intranasal doses of 10(7.0) fluorescent focus units of A/Anhui/1/2013 pLAIV (younger subjects)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Single dose of A/Anhui/1/2013 pLAIV (older subjects)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Single 30-µg dose of unadjuvanted, antigenically matched A/Shanghai2/2013(H7N9) pandemic inactivated influenza vaccine (pIIV)
Number of subjects: 49
Study: 26655846

Group type: EXPERIMENTAL
Intervention: PF-03446962 (10 mg/kg, recommended phase II dose 7 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PF-03446962 (0.5 to 15 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PF-03446962
Number of subjects: 44
Study: 26655919

Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnosed by ultrasound measurement of rectus femoris cross-sectional area
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Frailty diagnosed by the Frailty Index Questionnaire
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sarcopenia and frailty models
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sarcopenia and frailty
Number of subjects: 102
Study: 26656011

Group type: EXPERIMENTAL
Intervention: Annual health assessments including questionnaire, physical examination, ECG, blood and urine analysis.
Number of subjects: 32404
Study: 26656277

Group type: EXPERIMENTAL
Intervention: QLT091001 (40 mg/m2/day for 7 days)
Number of subjects: 18
Study: 26656373

Group type: EXPERIMENTAL
Intervention: Shapiro score
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte count ratio (NLCR)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Combination of Shapiro score with PCT levels
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Shapiro score ≥4 or PCT > 0.1 μg/L
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Shapiro score ≥3 or PCT >0.25 μg/L
Number of subjects: 1083
Study: 26657810

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) for 6 months
Number of subjects: 20
Study: 26658492

Group type: EXPERIMENTAL
Intervention: u-healthcare group
Number of subjects: 70

Group type: COMPARATOR
Intervention: standard care group
Number of subjects: 70
Study: 26658889

Group type: EXPERIMENTAL
Intervention: First-line pazopanib
Number of subjects: 278
Study: 26659089

Group type: EXPERIMENTAL
Intervention: Rituximab (R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAK cells
Number of subjects: 0
Study: 26659107

Group type: EXPERIMENTAL
Intervention: Data collected from the international PCD registry
Number of subjects: 201
Study: 26659347

Group type: EXPERIMENTAL
Intervention: (68)Ga-PSMA-11
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (68)Ga-RM2
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (68)Ga-PSMA-11 and (68)Ga-RM2
Number of subjects: 7
Study: 26659569

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 0
Study: 26660428

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Number of subjects: 0
Study: 26662175

Group type: EXPERIMENTAL
Intervention: Subjective excessive daytime sleepiness (EDS) assessed by the Epworth Sleep Questionnaire (ESS) with a mean score of 5.6 ± 3.5.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Correlation analysis of RHV and LHV with ESS scores.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including age, gender, SDB severity, and hypoxia.
Number of subjects: 232
Study: 26663235

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26663671

Group type: EXPERIMENTAL
Intervention: Automatic Stimulation Mode (AutoStim) of the Model 106 Vagus Nerve Stimulation (VNS) Therapy System
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VNS Normal and Magnet Modes stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quality of life and seizure severity scores
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 20
Study: 26663686

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 16
Study: 26663719

Group type: EXPERIMENTAL
Intervention: Docetaxel 40 mg/m² for Category 1 patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m² for Category 2 patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Docetaxel 20 mg/m² for Category 3 patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Docetaxel for all categories
Number of subjects: 3

Group type: COMPARATOR
Intervention: Comparison with Child-Pugh and NCI Organ Dysfunction Working Group systems
Number of subjects: 3
Study: 26666244

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg p.o. BID and cetuximab 250 mg/m(2) weekly following a 400 mg/m(2) load
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selumetinib and cetuximab combination
Number of subjects: 33
Study: 26666256

Group type: EXPERIMENTAL
Intervention: New and more effective diagnostic procedures and targeted therapies against ACC
Number of subjects: 0
Study: 26666313

Group type: EXPERIMENTAL
Intervention: BMI decrease
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 474

Group type: COMPARATOR
Intervention: Minimal increase or decrease in BMI
Number of subjects: 474
Study: 26666380

Group type: EXPERIMENTAL
Intervention: 123I-mIBG imaging
Number of subjects: 777

Group type: COMPARATOR
Intervention: ICD implantation
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: H/M ratio from 123I-mIBG results
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 777
Study: 26666942

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (six-dose regimen)
Number of subjects: 60
Study: 26666998

Group type: EXPERIMENTAL
Intervention: Denosumab alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: BP pre-treated group
Number of subjects: 22
Study: 26667027

Group type: EXPERIMENTAL
Intervention: Circulating DEHP metabolites exposure during PICU stay
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Validation cohort of DEHP metabolites exposure
Number of subjects: 449

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 449
Study: 26667382

Group type: EXPERIMENTAL
Intervention: 12 weeks of varenicline in combination with smoking cessation counseling
Number of subjects: 448
Study: 26668134

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone (LenDex)
Number of subjects: 31
Study: 26668712

Group type: EXPERIMENTAL
Intervention: Single-dose 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 72
Study: 26669474

Group type: EXPERIMENTAL
Intervention: Patients' self-reports during SBT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nurses' and physicians' assessments during SBT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients' perception of feeling secure and improvement of respiratory function
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Objective assessments of respiratory function
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Breathlessness during SBT and extubation outcome
Number of subjects: 100
Study: 26669916

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX)
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 1455
Study: 26670056

Group type: EXPERIMENTAL
Intervention: HeartMate 3 left ventricular assist system (LVAS)
Number of subjects: 50
Study: 26670070

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26670307

Group type: EXPERIMENTAL
Intervention: Colestilan (6-15 g/day)
Number of subjects: 116